Indoleamine 2,3-dioxygenase 1 (IDO1) is a key target for the development of small molecule immunotherapies in oncology. In this framework, the screening of chemotherapeutic agents to identify compounds binding to IDO1 represents a valuable strategy for the development of multitarget drug candidates that combine synergic immunoregulatory properties to cytotoxic activity. In this study, we report that two natural compounds endowed with anticancer activity, namely lapachol and auraptene, act as IDO1 ligands with dissociation constant (Kd) in the micromolar range of potency. Docking studies provide plausible binding modes of these compounds to the catalytic cleft of IDO1. Our results support the notion that lapachol and auraptene may be considered interesting lead compounds in the immuno-oncology setting.
MacchiaruloA., CamaioniE., NutiR., PellicciariR. (2009) Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids, 37, 219–229.
2.
(a) GrecoF.A., ColettiA., CamaioniE., CarottiA., MarinozziM., GioielloA., MacchiaruloA. (2016) The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities. Future Medicinal Chemistry, 8, 39–54; (b) Yeung AW, Terentis AC, King NJ, Thomas SR. (2015) Role of indoleamine 2,3-dioxygenase in health and disease. Clinical Science (London), 129, 601-672; (c) Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 281, 1191-1193.
3.
BallH.J., JusofF.F., BakmiwewaS.M., HuntN.H., YuasaH.J. (2014) Tryptophan-catabolizing enzymes - party of three. Frontiers in Immunology, DOI: 10.3389/fimmu.2014.00485.
4.
(a) GrohmannU., FallarinoF., PuccettiP. (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends in Immunology, 24, 242–248; (b) Mellor AL, Munn DH. (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Reviews Immunology, 4,762-74.
5.
(a) UyttenhoveC., PilotteL., ThéateI., StroobantV., ColauD., ParmentierN., BoonT., Van den EyndeB.J. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine, 9, 1269–1274; (b) Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. (2014) Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology and Immunotherapy, 63, 721-735; (c) Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, Ryckewaert T, Bessede A, Ghiringhelli F, Pulido M, Italiano A. (2017) Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. JAMA Oncology, doi: 10.1001/jamaoncol.2017.1617; (d) Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E. (2014) Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. The Journal of Clinical Endocrinology and Metabolism, 99, E832-40; (e) Liu XQ, Lu K, Feng LL, Ding M, Gao JM, Ge XL, Wang X. (2014) Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration. Leukemia & Lymphoma, 55, 405-414; (f) Liu H, Shen Z, Wang Z, Wang X, Zhang H, Qin J, Qin X, Xu J, Sun Y. (2016) Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Scientific Reports, 6, 21319.
6.
SheridanC. (2015) IDO inhibitors move center stage in immuno-oncology. Nature Biotechnology, 33, 321–322.
7.
(a) ColettiA., GrecoF.A., DolciamiD., CamaioniE., SardellaR., PallottaM.T., VolpiC., OrabonaC., GrohmannU., MacchiaruloA. (2017) Advances in indolemine 2,3-dioxygenase 1 medicinal chemistry: Structure-function and structure-activity relationships of the enzyme and its inhibitors. MedChemComm, 8, 1378–1392; (b) Jiang T, Sun Y, Yin Z, Feng S, Sun L, Li Z. (2015) Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Medicinal Chemistry, 7, 185-201; (c) Dolušić E, Frédérick R. (2013) Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012). Expert Opinion on Therapeutic Patents, 23, 1367-1381; (d) Coletti A, Camponeschi F, Albini E, Greco FA, Maione V, Custodi C, Ianni F, Grohmann U, Orabona C, Cantini F, Macchiarulo A. (2017) Fragment-based approach to identify IDO1 inhibitor building blocks. European Journal of Medicinal Chemistry, 141, 169-177.
8.
DelfourneE. (2012) Marine natural products and other derivatives as potent indoleamine 2,3-dioxygenase inhibitors. Mini Reviews in Medicinal Chemistry, 12, 988–996.
9.
(a) GaspariP., BanerjeeT., MalachowskiW.P., MullerA.J., PrendergastG.C., DuHadawayJ., BennettS., DonovanA.M. (2006) Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. Journal of Medicinal Chemistry, 49, 684–692; (b) Lu C, Lin Y, Yeh SR. Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase. (2009) Journal of the American Chemical Society, 131, 12866-12867.
10.
(a) FlickH.E., LalondeJ.M., MalachowskiW.P., MullerA.J. (2013) The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1. International Journal of Tryptophan Research, 6, 35–45; (b) Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ. (2008) Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. Journal of Medicinal Chemistry, 51, 1706-1718.
11.
DuhrS., BraunD. (2006) Why molecules move along a temperature gradient. Proceedings of the National Academy of Sciences of the United States of America, 103, 19678–19682.
12.
PengY.H., UengS.H., TsengC.T., HungM.S., SongJ.S., WuJ.S., LiaoF.Y., FanY.S., WuM.H., HsiaoW.C., HsuehC.C., LinS.Y., ChengC.Y., TuC.H., LeeL.C., ChengM.F., ShiaK.S., ShihC., WuS.Y. (2016) Important Hydrogen Bond Networks in Indoleamine 2,3-dioxygenase 1 (IDO1) Inhibitor Design revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. Journal of Medicinal Chemistry, 59, 282–293.
13.
RöhrigU.F., MajjigapuS.R., VogelP., ZoeteV., MichielinO. (2015) Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. Journal of Medicinal Chemistry, 58, 9421–9437.
14.
HussainH., GreenI.R. (2017) Lapachol and lapachone analogs: a journey of two decades of patent research (1997-2016). Expert Opinion on Therapeutic Patents, 27, 1111–1121.
15.
(a) OliveiraR.A., Azevedo-XimenesE., LuzzatiR., GarciaR.C. (2010) The hydroxy-naphthoquinone lapachol arrests mycobacterial growth and immunomodulates host macrophages. International Immunopharmacology, 10, 1463–73; (b) Peres RS, Santos GB, Cecilio NT, Jabor VA, Niehues M, Torres BG, Buqui G, Silva CH, Costa TD, Lopes NP, Nonato MC, Ramalho FS, Louzada-Júnior P, Cunha TM, Cunha FQ, Emery FS, Alves-Filho JC. (2017) Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis. Arthritis Research & Therapy, 19, 47.
16.
OgawaK., KawasakiA., YoshidaT., NesumiH., NakanoM., IkomaY., YanoM. (2000) Evaluation of auraptene content in citrus fruits and their products. Journal of Agricultural and Food Chemistry, 48, 1763–1769.
17.
DerosaG., MaffioliP., SahebkarA. (2016) Auraptene and Its Role in Chronic Diseases. Advances in Experimental Medicine and Biology, 929, 399–407.
18.
HasanM., GenoveseS., FioritoS., EpifanoF., Witt-EnderbyP.A. (2017) Oxyprenylated Phenylpropanoids Bind to MT1 Melatonin Receptors and Inhibit Breast Cancer Cell Proliferation and Migration. Journal of Natural Products, 80, 3324–3329.
19.
GaoX., FuT., WangC., NingC., KongY., LiuZ., SunH., MaX., LiuK., MengQ. (2017) Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury. Biochemical Pharmacology, 146, 127–138.
20.
GenoveseS., AshidaH., YamashitaY., NakganoT., IkedaM., DaishiS., EpifanoF., TaddeoV.A., FioritoS. (2017) The interaction of auraptene and other oxyprenylated phenylpropanoids with glucose transporter type 4. Phytomedicine, 32, 74–79.
21.
GrecoF.A., ColettiA., CustodiC., DolciamiD., MicheleA.D., CarottiA., MarinozziM., SchlinckN., MacchiaruloA. (2017) Binding properties of different categories of IDO1 inhibitors: a microscale thermophoresis study. Future Medicinal Chemistry, 12, 1327–1338.
22.
DuhrS., BraunD. (2006) Why molecules move along a temperature gradient. Proceedings of the National Academy of Sciences of the United States of America, 103, 19678–19682.
23.
(a) Schrödinger Release 2016-2: LigPrep, version 3.8, Schrödinger, LLC, New York, NY, 2016; (b) Schrödinger Release 2016-2: Maestro, version 10.6, Schrödinger, LLC, New York, NY, 2016.
24.
PengY.H., UengS.H., TsengC.T., HungM.S., SongJ.S., WuJ.S., LiaoF.Y., FanY.S., WuM.H., HsiaoW.C., HsuehC.C., LinS.Y., ChengC.Y., TuC.H., LeeL.C., ChengM.F., ShiaK.S., ShihC., WuS.Y. (2016) Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. Journal of Medicinal Chemistry, 59, 282–293.
25.
(a) FriesnerR.A., BanksJ.L., MurphyR.B., HalgrenT.A., KlicicJ.J., MainzD.T., RepaskyM.P., KnollE.H., ShelleyM., PerryJ.K., ShawD.E., FrancisP., ShenkinP.S. (2004) Glide: A New Approach for Rapid, Accurate Docking and Scoring. Journal of Medicinal Chemistry, 47, 1739–1759; (b) Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. (2006) Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49, 6177-6196; (c) Schrödinger Release 2016-2: Glide, version 7.1, Schrödinger, LLC, New York, NY, 2016.
